Table II.
Evidence which support the Docetaxel+Gemcitabine regimens are recommended to osteosarcoma.
| Authors | Number of patients | Drugs | Outcomes | (Refs.) |
|---|---|---|---|---|
| Yu et al | 39 | 21 cases: Gemcitabine (675 mg/m2 d1, d8)+docetaxel (100 mg/m2 d8) 18 cases: Pemetrexed (500 mg/m2d1)+ cisplatin (100 mg/m2 d1) | The response rate was 25.0% in patients who received pirarubicin-based chemotherapy, while it was 13.0% in the gemcitabine-docetaxel group. Moreover, the median OS was longer in the pirarubicin-based chemotherapy group (14.0 vs. 9.0 months, P<0.05), particularly in the pirarubicin-ifosfamide (14.0 months) and pirarubicin-cisplatin (15.0 months) subgroups. | (58) |
| He et al | 75 | 23 cases: Gemcitabine (675 mg/m2 d1, d8)+docetaxel (100 mg/m2 d8) 52 cases: THP-based chemotherapy (THP-CDDP, THP-IFO, or THP-PTX) | 13 patients (25.0%) in the THP group and 3 (13.0%) in the GT group achieved a PR, while 23 patients (44.2%) in the THP group and 8 (34.8%) in the GT group showed SD. Thus, RRs in the 2 groups were 25.0 and 13.0% (P=0.414), and DCRs were 69.2 and 47.8% (P=0.127) | (51) |
| Qi et al | 18 | Gemcitabine (675 mg/m2 d1, d8)+ docetaxel (100 mg/m2 d8) | The overall response rate was 5.6% and the disease control rate was 22.3%, with 1 partial response and 3 patients with stable disease. The median time to progression and overall survival time were 2 months (range: 2–6 months) and 8 months (range: 3–21 months) | (48) |
| Mora et al | 10 | Gemcitabine (675 mg/m2 d1, d8)+ docetaxel (100 mg/m2 d8) | 4 (40%) patients had a CR, 1 (10%) had a PR, 3 (30%) had SD and 2 (20%) had a PD, which provides an objective response rate (CR+PR) of 50%. Median duration of response (CR+PR+SD) was 10 months (range: 6 to 32+mo). 5 out of the 10 patients (50%) are alive, with a median follow-up of 48 months from diagnosis. | (59) |
| O'Day et al | 35 | Gemcitabine (675 mg/m2 d1, d8)+ docetaxel (100 mg/m2 d8) | All response rate 43%; 29% (CR+PR); 2 out of 4 osteosarcoma achieve PR. | (60) |
| Palmerini et al | 51 | Gemcitabine (900 mg/m2 d1, d8)+ docetaxel (75 mg/m2 d8) | Four-month PFS rate was 46%; 6 (13%) patients had a PR, 20 (43%) had SD and 20 (43%) had PD. The 1-year OS was 30%: 67% for PR, 54% for SD and 20% for PD (P=0.005). | (53) |
OS, osteosarcoma; THP, Therarubicin; GT, Gemcitabine+docetaxel; CR, complete response; PR, partial response; CDDP, cisplatin; IFO, ifosfamide; PTX, Paclitaxel; SD, stable disease; RR, Relative risk; DCR, Disease control rate; CR, control rate; PD, progressive disease; PFS, progression-free survival.